Financial Results (Consolidated Basis)

  • Total Revenue: Q1FY27: ₹6,675 Mn | Q1FY26: ₹4,907 Mn | YoY Growth: 36% | FY26: ₹23,836 Mn
  • EBITDA (including other income): Q1FY27: ₹1,749 Mn | Q1FY26: ₹1,292 Mn | YoY Growth: 35%
  • EBITDA Margin: Q1FY27: 26% | Q1FY26: 26% | FY26: 23%
  • Profit After Tax (PAT): Q1FY27: ₹512 Mn | Q1FY26: ₹485 Mn | YoY Growth: 6% | FY26: ₹2,222 Mn

Management Commentary

Mr. Anand Desai, Managing Director, commented on the performance:

  • The company began fiscal year 2027 with strong performance, achieving 36% YoY consolidated revenue growth
  • This reflects sustained momentum across businesses and execution of strategy to build a globally integrated specialty chemicals and CDMO platform

Technological Milestone

  • The company became the first in the world to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry
  • This represents a significant advancement in complex fluorination capabilities

Business Development

  • Signed a Letter of Intent with BASQUEVOLT, S.A. for potential long-term supply of a specialty chemical product
  • This represents a revenue opportunity of approximately US$300 million over a ten-year period

Acquisition Update

  • The proposed acquisition of Bliss GVS Pharma continues to progress as planned following the signing of the definitive agreement
  • Upon completion, the transaction is expected to strengthen the pharmaceutical platform through synergies across:
  • CDMO capabilities
  • Product development
  • Customer relationships
  • Access to regulated markets

Outlook

Management remains confident in growth prospects supported by:

  • Strong product pipeline
  • Expanding opportunities across Performance Materials and Pharmaceuticals segments
  • Deeper customer engagement
  • Continued investment in technology and innovation

Company Background

Anupam Rasayan India Limited is engaged in custom synthesis and manufacturing of specialty chemicals with two verticals:

1. Life science related Specialty Chemicals (Agrochemicals, Personal Care, Pharmaceuticals)

2. Other Specialty Chemicals (Polymer Additives)

Operates eight manufacturing facilities (six in Gujarat, one in Tamil Nadu, one in U.S.) with aggregate installed capacity of ~200,000+ MT as of March 31, 2026.

Disclaimer

The press release contains forward-looking statements subject to risks and uncertainties including changes in economic environment, tax laws, inflation, litigation, etc. Actual results may differ substantially.